

Shifting the Paradigm to Bariatric and Metabolic Surgery: The Solution for Obesity and Diabetes?

Michael D. Jensen, M.D. Endocrine Research Unit Mayo Clinic, Rochester, MN




50-year-old woman seen following RYGB – has lost 30 kg in 6 months and is no longer hungry. Which gut hormone changes might be helping reduce hunger?

Ghrelin
GLP-1
Oxyntomodulin
What the heck is oxyntomodulin?



Appetite Regulation






The Gut as an Endocrine Organ




- The gut is not a monolithic organ and comprises multiple cell types (neural, muscle, exocrine, endocrine)
- It is responsible for the integration of multiple peripheral and central signals necessary for the maintenance of body weight



Gut Hormones








Defects in Type 2 DM

- Despite elevated fasting insulin, insulin secretion is inappropriate for the degree of hyperglycemia
- Postprandial insulin responses are delayed and decreased in people with type 2 diabetes
- Suppression of postprandial glucagon secretion is also impaired in type 2 diabetes



... Other Factors in Diabetes



 The impaired suppression of endogenous glucose production is the major contributor to hyperglycemia in the postprandial period




Frank. Gastroenterology, 1995;109:755-765.

Effect of Bariatric Surgery on Diabetes

- A meta-analysis of 136 studies of bariatric surgery that included a total of 22,094 patients:
- 1417 of 1846 (76%) patients experienced complete resolution
- Diabetes resolved in 98.9% of patients undergoing DS
- 83.7% for RYGB and 47.9% for AGB



Diabetes Surgery Study



Ikramuddin. JAMA 2013;309:2240-2249


How Does Bariatric Surgery Help Diabetes?

- Restricted food intake?
- Rate of nutrient delivery/absorption?
- Gut hormones?




Effects of Caloric Restriction Comparable to Post-bariatric Surgery on Glucose





Pramlintide and Postprandial Glucose AUC




Gastric emptying may influence blood glucose


Vella. Neurogastroenterol Motil. 2002;14:123-131.



The Incretin Effect








Differences in function during antagonist administration can be attributed to the actions of GLP-1



Controls






Shah. Diabetes. 2014;63(2) 483-493.

Controls

Glucose






Shah. Diabetes. 2014;63(2) 483-493.

Controls


C-Peptide





Shah. Diabetes. 2014;**63**(2) 483-493.








Shah. Diabetes. 2014;63(2) 483-493.

Controls






Shah. Diabetes. 2014;63(2) 483-493.

GLP-1 Effects After Roux-en-y Gastric Bypass

- Slight improvement in insulin secretion
- Slight reduction in rates of gastric emptying
- Slight improvement in post-meal glucose tolerance
- Some reduction in food intake (unpublished data A. Vella)



Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 3-Year Outcomes



012 MEMER | slide-21


Are Endoscopic Procedures the Next "Bariatric Surgery"?

- Gastric balloons resurfacing of 1990s approaches
- Barrier approaches to mimic nutrients bypassing duodenum
- Endoscopic suturing of stomach to mimic gastric sleeve
- Aspirate contents from stomach




Gastric EBTs





Small Bowel EBTs



Duodenal Sleeves



Gastroduodenojejunal Sleeves

Duodenal Mucosal Resurfacing








Other EBTs

Aspiration Therapy




Full Sense Device





Self-assembling Magnets for Endoscopy









% EWL at 12 months with Orbera IGB

Study name	Subgroup within study		Statistics for	% EWL				
		Mean	Lower limit	Upper limit	Total			
Sallet 2004	Orbera	50.900	44.777	57.023	85	→		
Herve 2005	Orbera	27.000	21.747	32.253	100			
Angrisani 2006	Orbera	27.100	25.001	29.199	82	•		
Ganesh 2006	Orbera	10.900	5.559	16.241	16	-0-		
Genco 2007	Orbera	21.300	17.900	24.700	129	•		
Crea 2008	Orbera	27.400	26.616	28.184	138	•		
Genco 2009	Orbera	35.100	33.961	36.239	80			
Ohta 2009	Orbera	14.000	2.913	25.087	8			
Al Kahtan 2009	Orbera	18.000	13.680	22.320	137	·••		
Mui 2010	Orbera	32.900	21.325	44.475	68	∔ ●—		
Genco 2010	Orbera	25.100	17.838	32.362	50	- • -		
Nikolic 2011_1	Orbera	27.800	15.300	40.300	19	_ _		
Nickolic 2011_2	Orbera	37.400	22.437	52.363	24	<u>+</u> ●→		
Kotzampassi 2012	Orbera	43.000	41.127	44.873	384	•		
Bozkurt_1_2012	Orbera	30.900	18.248	43.552	15			
Bozkurt_2	Orbera	22.500	17.509	27.491	68	- e ¦-		
Bozkurt_3	Orbera	13.500	9.917	17.083	57	·••		
Boskurt_4	Orbera	12.300	8.741	15.859	62			
Boskurt_5	Orbera	4.700	0.667	8.733	18	•		
Farina 2012	Orbera	34.900	31.495	38.305	14	•		
Dogan 2013	Orbera	16.700	9.743	23.657	50			
Fuller 2013	Orbera	32.700	23.900	41.500	31			
	Random	25.441	21.457	29.426				



Dayyeh, et al. Gastrointest Endosc. 2015;82(3):425-38. EWL, excess weight loss


Mean difference in % EWL between Orbera IGB and control groups in RCTs

Study name	Statistics for each study					Comula sina		% EWL for IGB		
Study name	Statistics for each study				San	nple size				
	Difference in Mean	Lower limit	Upper limit	Р	IGB	Control				
Genco 2006	31.900	29.498	34.302	0.000	16	16		•		
Fuller 2013	33.400	17.627	49.173	0.000	31	35		—●		
Mohammed 2014	17.300	10.560	24.040	0.000	84	44		+ ●-		
Random	26.956	15.666	38.246	0.000					•	
							0.00	25.00	50.00	
							15%			



Dayyeh, et al. Gastrointest Endosc. 2015;82(3):425-38.


%EWL with Orbera IGB at a range of base-line BMI



Dayyeh, et al. Gastrointest Endosc. 2015;82(3):425-38.


mayo

ReShape Duo Intragastric Balloon



ReShape Duo IGB Pivotal US RCT: REDUCE Trial

%EWL at 24 weeks (balloon removal)




%EWL at 48 weeks (24 weeks after IGB removal) 18.8%




Ponce et al. Surg Obes Relat Dis. 2015 Jul-Aug;11(4):874-81


How to Achieve Better Weight Loss Results with Procedures



mavo

Endoscopic Sleeve Gastroplasty - Evolution








mavo

Dayyeh and Gostout GIE 2013 Sep;78(3):530-5 Abu Dayyeh et al. CGH 2016; DOI: http://dx.doi.org/10.1016/j.cgh.2015.12.030.

ESG Multi-Center Study: 242 Patients





Lopez-Nava, et al. Gastroenterology.2015;

US Pivotal Randomized Study PATHWAY Study

173 Subject / randomized open-label 10 center study. Study completed

Data being evaluated by FDA

Expect approval early next year




Gut and Adipose Hormone Approaches for Appetite Regulation

- CCK agonists
- GLP-1 agonists
- **PYY**₃₋₃₆
- Oxyntomodulin
- Ghrelin
- Leptin




Liraglutide Weight Loss Results



mayo

Liraglutide Side Effects




Percentage of individuals with nausea; each individual who withdrew because of nausea is shown by a red symbol.



Astrup et al. Lancet. 2009;374:1606 – 1616.

PYY₃₋₃₆ and Oxyntomodulin

- Oxyntomodulin is a GLP-1 receptor agonist
- These hormones are cosecreted by intestinal L cells in response to meals
- Co-infusion results in substantial reductions in food intake




*** P<0.001 vs saline ‡ P<0.05 vs PYY₃₋₃₆ + OXM ‡‡ P<0.01 vs PYY₃₋₃₆ + OXM




PYY₃₋₃₆ and Oxyntomodulin

- Higher doses of PYY₃₋₃₆ needed to best reduce food intake
- Also associated with greater ratings of nausea
- When those without nausea excluded the reduction in food intake from combined Rx was ~ 1/3



PYY₃₋₃₆ and GLP-1


• Similar to finding with PYY_{3-36} and oxyntomodulin, co-infusion of PYY_{3-36} and GLP-1 results in greater reductions in food intake than single infusions of either.






Neary et al. Endocrinology 2005;146: 5120–5127.

PYY₃₋₃₆ and GLP-1





Co-infusion of PYY₃₋₃₆ and GLP-1 results in similar changes in regional brain appetite center metabolism as meal ingestion.




Ghrelin

- Originally described as a peptide produced primarily by the stomach that stimulates GH secretion
- Found to be an orexigenic molecule
- Ghrelin levels increase between meals and fall after meals
- Therapeutic value of ghrelin antagonists unproven




Serum Ghrelin Before and After Weight Loss





Serum Ghrelin After Gastric Bypass Surgery





Summary

- Several GI hormones clearly regulate appetite
- Although they require injection, there seem to be fewer "off target" effects than with other approaches
- Whether endoscopic procedure, gut hormone administration or some combination will replace bariatric surgery is unknown





Cardiometabolic Health Congress • March 4-5 • San Francisco, CA